Recent News

• 02.09.2026 - bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
• 01.07.2026 - bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
• 12.03.2025 - bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
• 11.14.2025 - bioAffinity Technologies Reports Third Quarter 2025 Financial Results
• 11.05.2025 - bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
• 10.28.2025 - bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

Recent Filings

• 02.04.2026 - 8-K Current report
• 01.07.2026 - EX-99.1 EX-99.1
• 01.07.2026 - 8-K Current report
• 12.22.2025 - 8-K Current report
• 12.19.2025 - 8-K Current report
• 12.03.2025 - 8-K Current report
• 12.03.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 8-K Current report
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.14.2025 - EX-99.1 EX-99.1